BioLineRx Announces BL-8040 in Combination With KEYTRUDA Shows Clinical Activity in Heavily Pretreated Metastatic Pancreatic Cancer Patients
BioLineRx Ltd. - American Depositary Shares (BLRX)
Last biolinerx ltd. - american depositary shares earnings: 5/14 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.biolinerx.com
Company Research
Source: PR Newswire
TEL AVIV, Israel, Nov. 5, 2019 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) and (TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology, announced today results of a Phase 2b trial assessing the efficacy of BL-8040 in combination with KEYTRUDA® (pembrolizumab) for the treatment of metastatic pancreatic cancer. The data demonstrated that the dual combination shows clinical activity in heavily pretreated patients. The results of this investigator-sponsored study will be presented by MD Anderson Cancer Center in a poster titled, "A phase IIB study of Pembrolizumab plus BL-8040 in metastatic pancreatic cancer: Clinical outcomes and biological correlates," at the Society for Immunotherapy of Cancer (SITC) 34th Annual Meeting, which is being held November 6-10, 2019 in National Harbor, Maryland. "These promising data demonstrate that the dual combination of BL-8040 and KEYTRUDA shows encouraging clinical activity even in an extremely challenging patient population of h
Show less
Read more
Impact Snapshot
Event Time:
BLRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BLRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BLRX alerts
High impacting BioLineRx Ltd. - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
BLRX
News
- BioLineRx Ltd. (NASDAQ: BLRX) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.MarketBeat
- BioLineRx Ltd. (NASDAQ: BLRX) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.MarketBeat
- Silexion Therapeutics Appoints Renowned Cancer Therapeutics Expert Prof. Amnon Peled to Board of Directors [Yahoo! Finance]Yahoo! Finance
- BioLineRx Ltd. (NASDAQ: BLRX) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.MarketBeat
- BioLineRx Ltd. (NASDAQ: BLRX) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.MarketBeat
BLRX
Earnings
- 5/28/24 - Beat
BLRX
Analyst Actions
- 11/6/24 - HC Wainwright
BLRX
Sec Filings
- 11/25/24 - Form 6-K
- 11/21/24 - Form 6-K
- 11/21/24 - Form 424B5
- BLRX's page on the SEC website